Alzheimer's disease : Peptide vaccine and immunotherapy

Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD) the ẞ-amyloid peptide (Aẞ) and tau are promising therapeutic avenues against AD. Two decades of effort has led to the controversial United States Food and Drug Administration (FDA) approval of the monoclonal antibody Aducamumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target Aẞ.